Respiratory

Filter

Physician assessing an older patient’s breathing during a COPD consultation.

ATS 2026: Itepekimab COPD Trial Shows Mixed Results

May 2026

Itepekimab reduced COPD exacerbations in one Phase III trial, but the effect was not replicated across AERIFY-2.

Clinician discussing smoking and quitting behaviors with an adult patient, reflecting socioeconomic position differences.

Smoking And Quitting Behaviors Vary by Socioeconomic Position

Smoking and quitting behaviors in England 2014 to 2023 show clear socioeconomic disadvantage tied to smoking and addiction overall.

Patient holding travel documents while speaking with a public health nurse about tuberculosis treatment continuity of care

Continuity of Care Improves TB Treatment Completion

A CureTB analysis found: 79% treatment completion after international relocation, with timelier linkage improving outcomes overall.

Infusion chair and IV setup with a clock motif, reflecting time-of-day immunochemotherapy in advanced NSCLC.

Time-of-Day Immunochemotherapy Improves NSCLC Survival

Retrospective signals have suggested that treatment timing may influence immunochemotherapy efficacy, but prospective evidence has been limited.

COPD inhaler in a patient’s hand illustrating COPD exacerbation risk after stopping LAMA or ICS

COPD Exacerbation Risk Spikes After Stopping LAMA or ICS

Stopping LAMA or ICS in COPD, raised exacerbation risk for three months, with pronounced withdrawal-associated spikes.

Oral glucose tolerance test blood draw for cystic fibrosis-related diabetes biomarker research

New Cystic Fibrosis-Related Diabetes Biomarkers Emerge

Circulating microRNAs shifted during OGTT, distinguishing cystic fibrosis-related diabetes from earlier intolerance in CF cohorts.

Patient with persistent cough during diabetes medication review, concept image for GLP-1 receptor agonists and chronic cough

Do GLP-1 Receptor Agonists Raise Chronic Cough Risk?

GLP-1 receptor agonists were associated with increased incident chronic cough among adults with type 2 diabetes, in US EHR records.

Patient with clinician beside CT scanner during NSCLC imaging assessment.

NSCLC Progression Type Predicts Survival

In advanced NSCLC, progression by new lesions predicted shorter post-progression survival following first-line therapy.

Hand sprinkling salt into a bowl on a dark background, illustrating salt intake advice in cystic fibrosis under review after ETI therapy.

Salt Intake Advice in Cystic Fibrosis Under Review

Salt intake advice in cystic fibrosis is under review after ETI improved conservation and blood pressure.

Loading posts...

« Previous 1 … 4 5 6 7 8 … 35 Next »